Clinical perspectives from the BEGIN and EDITION programmes: Trial-level meta-analyses outcomes with either degludec or glargine 300 U/mL vs glargine 100 U/mL in T2DM

Diabetes and Metabolism

Volumn 44, Issue 5, 2018, Pages 402-409

  Roussel, R ^a,b,c   Ritzel, R ^d   Boelle Le Corfec E ^e   Balkau, B ^f,g,h   Rosenstock, J ⁱ  

^a CENTRE DE RECHERCHE DES CORDELIERS   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c BICHAT HOSPITAL   (France)

^d KLINIKUM BOGENHAUSEN   (Germany)

^e SANOFI   (France)

^f CENTRE FOR RESEARCH IN EPIDEMIOLOGY AND POPULATION HEALTH   (France)

^g LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^h UNIVERSITÉ PARIS SACLAY   (France)

ⁱ Dallas Diabetes and Endocrine Center at Medical City   (United States)

Author keywords

Insulin degludec; Insulin glargine 300 U mL; Phase 3 clinical trials; Trial level meta analyses; Type 2 diabetes mellitus

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN DEGLUDEC; INSULIN GLARGINE; ORAL ANTIDIABETIC AGENT; ANTIDIABETIC AGENT; LONG ACTING INSULIN;

ARTICLE; COMPARATIVE EFFECTIVENESS; DRUG DOSE COMPARISON; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; BLOOD; CHEMICALLY INDUCED; INCIDENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INCIDENCE; INSULIN GLARGINE; INSULIN, LONG-ACTING; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 85043471387     PISSN: 12623636     EISSN: 18781780     Source Type: Journal    
DOI: 10.1016/j.diabet.2018.02.002     Document Type: Article

References (30)

1. Lepore, M., Pampanelli, S., Fanelli, C., Porcellati, F., Bartocci, L., Di Vincenzo, A., et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 49 (2000), 2142–2148.
2. Heinemann, L., Sinha, K., Weyer, C., Loftager, M., Hirschberger, S., Heise, T., Time-action profile of the soluble, fatty acid acylated, long-acting insulin analogue NN304. Diabet Med 16 (1999), 332–338.
3. Yki-Jarvinen, H., Kauppinen-Makelin, R., Tiikkainen, M., Vahatalo, M., Virtamo, H., Nikkila, K., et al. Insulin glargine or NPH combined with metformin in type-2 diabetes: the LANMET study. Diabetologia 49 (2006), 442–451.
4. Philis-Tsimikas, A., Charpentier, G., Clauson, P., Ravn, G.M., Roberts, V.L., Thorsteinsson, B., Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral anti-diabetic drugs in poorly controlled type-2 diabetes. Clin Ther 28 (2006), 1569–1581.
5. Heise, T., Nosek, L., Bottcher, S.G., Hastrup, H., Haahr, H., Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type-2 diabetes. Diabetes Obes Metab 14 (2012), 944–950.
6. Becker, R.H., Dahmen, R., Bergmann, K., Lehmann, A., Jax, T., Heise, T., New insulin glargine 300 Units.mL-1 provides a more even activity profile and prolonged glycaemic control at steady state compared with insulin glargine 100 Units.mL-1. Diabetes Care 38 (2015), 637–643.
7. Garber, A.J., King, A.B., Del Prato, S., Sreenan, S., Balci, M.K., Munoz-Torres, M., et al. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type-2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet 379 (2012), 1498–1507.
8. Zinman, B., Philis-Tsimikas, A., Cariou, B., Handelsman, Y., Rodbard, H.W., Johansen, T., et al. Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long). Diabetes Care 35 (2012), 2464–2471.
9. Gough, S.C., Bhargava, A., Jain, R., Mersebach, H., Rasmussen, S., Bergenstal, R.M., Low-volume insulin degludec 200 Units/mL once daily improves glycaemic control similarly to insulin glargine with a low risk of hypoglycaemia in insulin-naive patients with type 2 diabetes: a 26-week, randomized, controlled, multinational, treat-to-target trial: the BEGIN LOW VOLUME trial. Diabetes Care 36 (2013), 2536–2542.
10. Meneghini, L., Atkin, S.L., Gough, S.C., Raz, I., Blonde, L., Shestakova, M., et al. The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes. Diabetes Care 36 (2013), 858–864.
11. Onishi, Y., Iwamoto, Y., Yoo, S.J., Clauson, P., Tamer, S.C., Park, S., Insulin degludec compared with insulin glargine in insulin-naive patients with type 2 diabetes: a 26-week, randomized, controlled, Pan-Asian, treat-to-target trial. J Diabetes Investig 4 (2013), 605–612.
12. Riddle, M.C., Bolli, G.B., Ziemen, M., Muehlen-Bartmer, I., Bizet, F., Home, P.D., et al. New insulin glargine 300 Units/mL versus glargine 100 Units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycaemia in a 6-month randomized controlled trial (EDITION 1). Diabetes Care 37 (2014), 2755–2762.
13. Yki-Jarvinen, H., Bergenstal, R., Ziemen, M., Wardecki, M., Muehlen-Bartmer, I., Boelle, E., et al. New insulin glargine 300 Units/mL versus glargine 100 Units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycaemia in a 6-month randomized controlled trial (EDITION 2). Diabetes Care 37 (2014), 3235–3243.
14. Bolli, G.B., Riddle, M.C., Bergenstal, R.M., Ziemen, M., Sestakauskas, K., Goyeau, H., et al. New insulin glargine 300 U/mL compared with glargine 100 U/mL in insulin-naive people with type-2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3). Diabetes Obes Metab 17 (2015), 386–394.
15. Terauchi, Y., Koyama, M., Cheng, X., Takahashi, Y., Riddle, M.C., Bolli, G.B., et al. New insulin glargine 300 U/mL versus glargine 100 U/mL in Japanese people with type-2 diabetes using basal insulin and oral anti-hyperglycaemic drugs: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 2). Diabetes Obes Metab 18 (2016), 366–374.
16. Ratner, R.E., Gough, S.C., Mathieu, C., Del Prato, S., Bode, B., Mersebach, H., et al. Hypoglycaemia risk with insulin degludec compared with insulin glargine in type-2 and type-1 diabetes: a pre-planned meta-analysis of phase 3 trials. Diabetes Obes Metab 15 (2013), 175–184.
17. Ritzel, R., Roussel, R., Bolli, G.B., Vinet, L., Brulle-Wohlhueter, C., Glezer, S., et al. Patient-level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/mL versus glargine 100 U/mL in people with type-2 diabetes. Diabetes Obes Metab 17 (2015), 859–867.
18. Heise, T., Norskov, M., Nosek, L., Kaplan, K., Famulla, S., Haahr, H.L., Insulin degludec: lower day-to-day and within-day variability in pharmacodynamic response compared with insulin glargine 300 U/mL in type-1 diabetes. Diabetes Obes Metab 19 (2017), 1032–1039.
19. Bailey, T.S., Pettus, J., Roussel, R., Schmider, W., Maroccia, M., Nassr, N., et al. Morning administration of 0.4 U/kg/day insulin glargine 300 U/mL provides less fluctuating 24 hour pharmacodynamics and more even pharmacokinetic profiles compared with insulin degludec 100 U/mL in type-1 diabetes. Diabetes Metab 44 (2017), 15–21.
20. Russell-Jones, D., Gall, M.A., Niemeyer, M., Diamant, M., Del Prato, S., Insulin degludec results in lower rates of nocturnal hypoglycaemia and fasting plasma glucose vs. insulin glargine: a meta-analysis of seven clinical trials. Nutr Metab Cardiovasc Dis 25 (2015), 898–905.
21. Vora, J., Christensen, T., Rana, A., Bain, S.C., Insulin degludec versus insulin glargine in type-1 and type-2 diabetes mellitus: a meta-analysis of endpoints in phase 3a trials. Diabetes Ther 5 (2014), 435–446.
22. Wysham, C., Bhargava, A., Chaykin, L., de la Rosa, R., Handelsman, Y., Troelsen, L.N., et al. Effect of insulin degludec vs insulin glargine U100 on hypoglycaemia in patients with type-2 diabetes: The SWITCH 2 Randomized Clinical Trial. JAMA 318 (2017), 45–56.
23. Novo Nordisk, SWITCH 2 Clinical Trial Report. 2016 [Accessed 6 Jun. 2017; http://novonordisk-trials.com/Website/pdf/registry/48438-3998-ctr-redacted.pdf].
24. Novo, Nordisk, FDA Briefing Document. Insulin degludec and insulin degludec/insulin aspart treatment to improve glycaemic control in patients with diabetes mellitus. NDAs 203314 and 203313. 2012 [Accessed 29 Sept 2016; http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM327017.pdf].
25. Novo Nordisk, Find clinical trials. 2016 [Accessed 29 Sept 2016; http://novonordisk-trials.com/website/search/trialsearch.aspx].
26. ® in insulin-naive patients with type 2 diabetes mellitus inadequately controlled with oral anti-hyperglycaemic drug(s) ± GLP-1 receptor agonist. 2016 [Accessed 20 Oct 2016; https://clinicaltrials.gov].
27. Freemantle, N., Chou, E., Frois, C., Zhuo, D., Lehmacher, W., Vlajnic, A., et al. Safety and efficacy of insulin glargine 300 u/mL compared with other basal insulin therapies in patients with type-2 diabetes mellitus: a network meta-analysis. BMJ Open, 6, 2016, e009421.
28. American Diabetes Association, Glycaemic Targets. Sec. 5. In Standards of medical care in Diabetes–2016. Diabetes Care 39:Suppl 1 (2016), S39–S46.
29. Marso, S.P., McGuire, D.K., Zinman, B., Poulter, N.R., Emerson, S.S., Pieber, T.R., et al. Efficacy and safety of degludec versus glargine in type-2 diabetes. N Engl J Med 377 (2017), 723–732.
30. Riddle, M.C., Yki-Jarvinen, H., Bolli, G.B., Ziemen, M., Muehlen-Bartmer, I., Cissokho, S., et al. One-year sustained glycaemic control and less hypoglycaemia with new insulin glargine 300 U/mL compared with 100 U/mL in people with type-2 diabetes using basal plus mealtime insulin: the EDITION 1 12-month randomized trial, including 6-month extension. Diabetes Obes Metab 17 (2015), 835–842.